



## PUBLIKATIONEN AUS DER KLINIK FÜR PSYCHIATRIE UND PSYCHOTHERAPIE DER UNIVERSITÄT MÜNCHEN 2010

1. **AthanasIU L, Mattingsdal M, Kähler AK, Brown A, Gustafsson O, Agartz I, Giegling I, Muglia P, Cichon S, Rietschel M, Pietiläinen OP, Peltonen L, Bramon E, Collier D, Clair DS, Sigurdsson E, Petursson H, Rujescu D, Melle I, Steen VM, Djurovic S, Andreassen OA**  
Gene variants associated with schizophrenia in a Norwegian genome-wide study are replicated in a large European cohort.  
J Psychiatr Res 2010; 44: 748-753.
2. **Baghai TC, Möller H-J, Nitschmann S**  
Effektivität der antidepressiven Therapie bei Patienten mit mäßig ausgeprägter depressiver Symptomatik.  
Internist 2010; 51: 1456-1458.
3. **Bajbouj M, Merkl A, Schlaepfer TE, Frick C, Zobel A, Maier W, O'Keane V, Corcoran C, Adolfsson R, Trimble M, Rau H, Hoff HJ, Padberg F, Müller-Siecheneder F, Audenaert K, van den AD, Matthews K, Christmas D, Eljamel S, Heuser I**  
Two-year outcome of vagus nerve stimulation in treatment-resistant depression.  
J Clin Psychopharmacol 2010; 30: 273-281.
4. **Benninghoff J, Gritti A, Rizzi M, Lamorte G, Schloesser RJ, Schmitt A, Robel S, Genius J, Moessner R, Riederer P, Manji HK, Grunze H, Rujescu D, Möller H-J, Lesch KP, Vescovi AL**  
Serotonin depletion hampers survival and proliferation in neurospheres derived from adult neural stem cells.  
Neuropsychopharmacology 2010; 35: 893-903.

5. **Blauw HM, Al Chalabi A, Andersen PM, van Vught PW, Diekstra FP, van Es MA, Saris CG, Groen EJ, van Rheenen W, Koppers M, Van't Slot R, Strengman E, Estrada K, Rivadeneira F, Hofman A, Uitterlinden AG, Kiemeney LA, Vermeulen SH, Birve A, Waibel S, Meyer T, Cronin S, McLaughlin RL, Hardiman O, Sapp PC, Tobin MD, Wain LV, Tomik B, Slowik A, Lemmens R, Rujescu D, Schulte C, Gasser T, Brown RH, Jr., Landers JE, Robberecht W, Ludolph AC, Ophoff RA, Veldink JH, van den Berg LH**  
A large genome scan for rare CNVs in amyotrophic lateral sclerosis.  
Hum Mol Genet 2010; 19: 4091-4099.
  
6. **Bokde AL, Karmann M, Born C, Teipel SJ, Omerovic M, Ewers M, Frodl T, Meisenzahl E, Reiser M, Möller H-J, Hampel H**  
Altered Brain Activation During a Verbal Working Memory Task in Subjects with Amnesic Mild Cognitive Impairment.  
J Alzheimers Dis 2010; 21: 103-118.
  
7. **Bokde AL, Lopez-Bayo P, Born C, Ewers M, Meindl T, Teipel SJ, Faltraco F, Reiser MF, Möller H-J, Hampel H**  
Alzheimer disease: functional abnormalities in the dorsal visual pathway.  
Radiology 2010; 254: 219-226.
  
8. **Bondy B**  
Psychopharmaka. Kleine Helfer oder chemische Keule?  
Becksche Reihe, München, 2010.
  
9. **Bondy B, Spellmann I, Musil R, Zill P, Müller N, Möller H-J, Riedel M**  
Die Bedeutung der Pharmakogenetik für die antipsychotische Therapie  
In: Möller H-J, Müller N (Hrsg.)  
Schizophrenie – Zukunftsperspektiven in Klinik und Forschung.  
Springer, Wien, 2010, S. 219-227.
  
10. **Born C, Zimmermann R, Möller H-J, Baghai TC**  
Grundlagen der Arzneimitteltherapie unipolarer depressiver Erkrankungen.  
Internist Prax 2010; 50: 835-852.
  
11. **Bottlender R, Strauß A, Möller H-J**  
Social disability in schizophrenic, schizoaffective and affective disorders 15 years after first admission.  
Schizophr Res 2010; 116: 9-15.

12. **Borgwardt SJ, Picchioni MM, Ettinger U, Touloupoulou T, Murray R, McGuire P**  
Regional gray matter volume in monozygotic twins concordant and discordant for schizophrenia.  
Biol Psychiatry 2010; 67: 956-964.
13. **Braam AW, Beekman AT, Dewey ME, Delespaul PA, Fichter M, Lobo A, Magnússon H, Pérès K, Reischies FM, Roelands M, Saz P, Schoevers RA, Skoog I, Copeland JR**  
Depression and parkinsonism in older Europeans: results from the EURODEP concerted action.  
Int J Geriatr Psychiatry 2010; 25: 679-687.
14. **Buschert V, Bokde AL, Hampel H**  
Cognitive intervention in Alzheimer disease.  
Nat Rev Neurol 2010; 6: 508-517.
15. **Cañas F, Möller H-J**  
Long-acting atypical injectable antipsychotics in the treatment of schizophrenia: safety and tolerability review.  
Expert Opin Drug Saf 2010; 9: 683-697.
16. **Carroll LS, Williams NM, Moskvina V, Russell E, Norton N, Williams HJ, Peirce T, Georgieva L, Dwyer S, Grozeva D, Greene E, Farmer A, McGuffin P, Morris DW, Corvin A, Gill M, Rujescu D, Sham P, Holmans P, Jones I, Kirov G, Craddock N, O'Donovan MC, Owen MJ**  
Evidence for rare and common genetic risk variants for schizophrenia at protein kinase C, alpha.  
Mol Psychiatry 2010; 15: 1101-1111.
17. **Crawford TJ, Hamm JP, Kean M, Schmechtig A, Kumari V, Anilkumar AP, Ettinger U**  
The perception of real and illusory motion in schizophrenia.  
Neuropsychologia 2010; 48: 3121-3127.
18. **Damm J, Eser D, Möller H-J, Rupprecht R**  
Severe dependency on zolpidem in a patient with multiple sclerosis suffering from paraspasticity.  
World J Biol Psychiatry 2010; 11: 516-518.

19. **Damm J, Eser D, Schüle C, Obermeier M, Möller H-J, Rupprecht R, Baghai TC**  
Influence of age on effectiveness and tolerability of electroconvulsive therapy.  
J ECT 2010; 26: 282-288.
20. **de Hert M, Dekker J, Wood D, Kahl K, Holt R, Möller H-J**  
Cardiovasculaire ziekte en diabetes bij mensen met een ernstige psychiatrische stoornis. Position statement van de European Psychiatric Association (EPA), ondersteund jdoor de European Association fort he Study of Diabetes (EASD) en de european Study of Cardiology (ESC).  
Tijdschr voor Geneeskunde 2010; 66: 269-281.
21. **de Hert M, Dekker JM, Wood D, Kahl KG, Holt RIG, Möller H-J**  
Eine Konsensus-Erklärung der European Psychiatric Association (EPA) zu kardiovaskulären Erkrankungen und Diabetes bei Patienten mit einer schweren psychischen Erkrankung. Unterstützt von der European Association for the Study of Diabetes (EASD) und der European Society of Cardiology (ESC).  
Psychopharmakotherapie 2010; 17: 3-13.
22. **Dehning S, Müller N, Matz J, Bender A, Kerle I, Benninghoff J, Musil R, Spellmann I, Bondy B, Möller H-J, Riedel M, Zill P**  
A genetic variant of HTR2C may play a role in the manifestation of Tourette syndrome.  
Psychiatr Genet 2010; 20: 35-38.
23. **Dellava JE, Thornton LM, Hamer RM, Strober M, Plotnicov K, Klump KL, Brandt H, Crawford S, Fichter MM, Halmi KA, Jones I, Johnson C, Kaplan AS, Lavia M, Mitchell J, Rotondo A, Treasure J, Woodside DB, Berrettini WH, Kaye WH, Bulik CM**  
Childhood anxiety associated with low BMI in women with anorexia nervosa.  
Behav Res Ther 2010; 48: 60-67.
24. **Dittmann V, Müller N, Möller H-J**  
Prof. Dr. med. Franz Müller-Spahn. Nachruf.  
Nervenarzt 2010; 81: 95-96.

25. **Domenici E, Wille DR, Tozzi F, Prokopenko I, Miller S, McKeown A, Brittain C, Rujescu D, Giegling I, Turck CW, Holsboer F, Bullmore ET, Middleton L, Merlo-Pich E, Alexander RC, Muglia P**  
Plasma protein biomarkers for depression and schizophrenia by multi analyte profiling of case-control collections.  
PLoS One 2010; 5: e9166.
26. **Egger C, Mühlbacher M, Grohmann R, Stuppäck C**  
Clozapine intoxication in a patient with lamotrigine-induced rash.  
Pharmacopsychiatry 2010; 43: 35-36.
27. **Ernst A, Bürger K, Hartmann O, Dodel R, Noelker C, Sommer N, Schwarz M, Köhrle J, Bergmann A, Hampel H**  
Midregional Proenkephalin A and N-terminal protachykinin A are decreased in the cerebrospinal fluid of patients with dementia disorders and acute neuroinflammation.  
J Neuroimmunol 2010; 221: 62-67.
28. **Ertl M, Kirsch V, Leicht G, Karch S, Olbrich S, Reiser M, Hegerl U, Pogarell O, Mulert C**  
Avoiding the ballistocardiogram (BCG) artifact of EEG data acquired simultaneously with fMRI by pulse-triggered presentation of stimuli.  
J Neurosci Methods 2010; 186: 231-241.
29. **Erzberger CS, Engel RR**  
Zur Äquivalenz der Normen des Wechsler-Intelligenztests für Erwachsene (WIE) mit denen des Hamburg-Wechsler-Intelligenztests für Erwachsene – Revision (HAWIE-R).  
Z Neuropsychol 2010; 21: 25-37.
30. **Eser D, Nothdurfter C, Schüle C, Damm J, Steng Y, Möller H-J, Rupprecht R, Baghai T**  
The influence of anaesthetic medication on safety, tolerability and clinical effectiveness of electroconvulsive therapy.  
World J Biol Psychiatry 2010; 11: 447-456.
31. **Falkai P, Möller H-J**  
Affective disorders: the role of the duration of untreated illness, suicidality and pharmacogenetics.  
Eur Arch Psychiatry Clin Neurosci 2010; 260: 365-366.

32. **Falkai P, Möller H-J**  
Biomarkers, population-based studies and a proof of principle investigation in pharmacotherapy.  
Eur Arch Psychiatry Clin Neurosci 2010; 260: 507-508.
33. **Falkai P, Möller H-J**  
Sleep, hypothalamus, and stigma.  
Eur Arch Psychiatry Clin Neurosci 2010; 260: 563-564.
34. **Falkai P, Möller H-J**  
Understanding mental disorders from neuronal networks to glial cells and proteomics.  
Eur Arch Psychiatry Clin Neurosci 2010; 260: 441-442.
35. **Fichter MM, Quadflieg N, Fischer UC, Kohlboeck G**  
Twenty-five-year course and outcome in anxiety and depression in the Upper Bavarian Longitudinal Community Study.  
Acta Psychiatr Scand 2010; 122: 75-85.
36. **Frodl T, Bokde AL, Scheuerecker J, Lisiecka D, Schoepf V, Hampel H, Möller H-J, Bruckmann H, Wiesmann M, Meisenzahl E**  
Functional connectivity bias of the orbitofrontal cortex in drug-free patients with major depression.  
Biol Psychiatry 2010; 67: 161-167.
37. **Frodl T, Reinhold E, Koutsouleris N, Donohoe G, Bondy B, Reiser M, Möller H-J, Meisenzahl EM**  
Childhood stress, serotonin transporter gene and brain structures in major depression.  
Neuropsychopharmacology 2010; 35: 1383-1390.
38. **Frodl T, Reinhold E, Koutsouleris N, Reiser M, Meisenzahl EM**  
Interaction of childhood stress with hippocampus and prefrontal cortex volume reduction in major depression.  
J Psychiatr Res 2010; 44: 799-807.

39. **Frodl T, Stauber J, Schaaff N, Koutsouleris N, Scheuerecker J, Ewers M, Omerovic M, Opgen-Rhein M, Hampel H, Reiser M, Möller H-J, Meisenzahl E**  
Amygdala reduction in patients with ADHD compared with major depression and healthy volunteers.  
Acta Psychiatr Scand 2010; 121: 111-118.
40. **Giegling I, Chiesa A, Mandelli L, Gibiino S, Hartmann AM, Möller H-J, Schneider B, Schnabel A, Maurer K, De Ronchi D, Rujescu D, Serretti A**  
Influence of neuronal cell adhesion molecule (NCAM1) variants on suicidal behaviour and correlated traits.  
Psychiatry Res 2010; 179: 222-225.
41. **Giegling I, Drago A, Schäfer M, Möller H-J, Rujescu D, Serretti A**  
Interaction of haloperidol plasma level and antipsychotic effect in early phases of acute psychosis treatment.  
J Psychiatr Res 2010; 44: 487-492.
42. **Giegling I, Genius J, Benninghoff J, Rujescu D**  
Genetic findings in schizophrenia patients related to alterations in the intracellular Ca-homeostasis.  
Prog Neuropsychopharmacol Biol Psychiatry 2010; 34: 1375-1380.
43. **Gillhoff K, Gaab J, Emini L, Maroni C, Tholuck J, Greil W**  
Effects of a multimodal lifestyle intervention on body mass index in patients with bipolar disorder: a randomized controlled trial.  
Prim Care Companion J Clin Psychiatry 2010; 12: e1-e8.
44. **Greil W, von Stralendorff I**  
Bipolare Störungen. Medikamentöse Therapie.  
In: Therapie psychischer Erkrankungen. State of the Art.  
Voderholzer U, Hohagen F (Hrsg). Elsevier, München, 2010, S. 180-191.
45. **Grohmann M, Hammer P, Walther M, Paulmann N, Büttner A, Eisenmenger W, Baghai TC, Schüle C, Rupprecht R, Bader M, Bondy B, Zill P, Priller J, Walther DJ**  
Alternative splicing and extensive RNA editing of human TPH2 transcripts.  
PLoS One 2010; 5: e8956.

46. **Grunze H, Dargel S**  
Akut- und Langzeittherapie der bipolaren Depression.  
Nervenarzt 2010; 81: 539-548.
47. **Grunze H, Vieta E, Goodwin GM, Bowden C, Licht RW, Möller H-J, Kasper S**  
The World Federation of Societies of Biological Psychiatry (WFSBP)  
Guidelines for the biological treatment of bipolar disorders: update 2010  
on the treatment of acute bipolar depression.  
World J Biol Psychiatry 2010; 11: 81-109.
48. **Häßler F, Kinze W, Nedopil N (Hrsg)**  
Praxishandbuch Forensische Psychiatrie des Kindes-, Jugend- und  
Erwachsenenalters.  
Medizinisch Wissenschaftliche Verlagsgesellschaft, Berlin, 2010.
49. **Haroldsson MH, Ettinger U, Magnúsdóttir BB, Ingason A, Hutton SB, Sigmundsson T, Sigurdsson E, Petursson H**  
Neuregulin-1 genotypes and eye movements in schizophrenia.  
Eur Arch Psychiatry Clin Neurosci 2010; 260: 77-85.
50. **Henkel V, Mergl R, Allgaier AK, Hautzinger M, Kohlen R, Coyne JC, Möller H-J, Hegerl U**  
Treatment of atypical depression: post-hoc analysis of a randomized  
controlled study testing the efficacy of sertraline and cognitive  
behavioural therapy in mildly depressed outpatients.  
Eur Psychiatry 2010; 25: 491-498.
51. **Hippius H, Rütger E**  
Nachruf auf Professor Dr. med. Franz Müller-Spahn.  
Fortschr Neurol Psychiat 2010; 78: 481-482.
52. **Hippius H, Rütger E**  
Prof. Dr. Norbert Matussek. Nachruf.  
Nervenarzt 2010; 81: 607-608.
53. **Höppner J, Berger C, Walter U, Padberg F, Buchmann J, Herwig U, Domes G**  
Influence of repetitive transcranial magnetic stimulation on special  
symptoms in depressed patients.  
Restor Neurol Neurosci 2010; 28: 577-585.



54. **Holzer M, Padberg F**  
Intermittent theta burst stimulation (iTBS) ameliorates therapy-resistant depression: a case series.  
Brain Stimul 2010; 3: 181-183.
55. **Ingason A, Giegling I, Cichon S, Hansen T, Rasmussen HB, Nielsen J, Jürgens G, Muglia P, Hartmann AM, Strengman E, Vasilescu C, Muhleisen TW, Djurovic S, Melle I, Lerer B, Möller H-J, Francks C, Pietiläinen OP, Lonnqvist J, Suvisaari J, Tuulio-Henriksson A, Walshe M, Vassos E, Di Forti M, Murray R, Bonetto C, Tosato S, Cantor RM, Rietschel M, Craddock N, Owen MJ, Peltonen L, Andreassen OA, Nöthen MM, St Clair D, Ophoff RA, O'Donovan MC, Collier DA, Werge T, Rujescu D**  
A large replication study and meta-analysis in European samples provides further support for association of AH11 markers with schizophrenia.  
Hum Mol Genet 2010; 19: 1379-1386.
56. **Jäger M, Möller H-J**  
Therapeutische Effekte von Haloperidol und Risperidon bei schizophrenen Ersterkrankten im Vergleich.  
In: Möller H-J, Müller N (Hrsg.)  
Schizophrenie – Zukunftsperspektiven in Klinik und Forschung.  
Springer, Wien, 2010, S. 197-204.
57. **Jäger M, Riedel M, Obermeier M, Schennach-Wolff R, Seemüller F, Messer T, Laux G, Pfeiffer H, Naber D, Schmidt LG, Gaebel W, Klosterkötter J, Heuser I, Kuhn KU, Lemke MR, Rüter E, Klingberg S, Gastpar M, Bottlender R, Möller H-J**  
Time course of antipsychotic treatment response in schizophrenia: results from a naturalistic study in 280 patients.  
Schizophr Res 2010; 118: 183-188.

58. **Jones L, Holmans PA, Hamshere ML, Harold D, Moskvina V, Ivanov D, Pocklington A, Abraham R, Hollingworth P, Sims R, Gerrish A, Pahwa JS, Jones N, Stretton A, Morgan AR, Lovestone S, Powell J, Proitsi P, Lupton MK, Brayne C, Rubinsztein DC, Gill M, Lawlor B, Lynch A, Morgan K, Brown KS, Passmore PA, Craig D, McGuinness B, Todd S, Holmes C, Mann D, Smith AD, Love S, Kehoe PG, Mead S, Fox N, Rossor M, Collinge J, Maier W, Jessen F, Schürmann B, van den BH, Heuser I, Peters O, Kornhuber J, Wiltfang J, Dichgans M, Frölich L, Hampel H, Hüll M, Rujescu D, Goate AM, Kauwe JS, Cruchaga C, Nowotny P, Morris JC, Mayo K, Livingston G, Bass NJ, Gurling H, McQuillin A, Gwilliam R, Deloukas P, Al Chalabi A, Shaw CE, Singleton AB, Guerreiro R, Mühleisen TW, Nöthen MM, Moebus S, Jöckel KH, Klopp N, Wichmann HE, Rüther E, Carrasquillo MM, Pankratz VS, Younkin SG, Hardy J, O'Donovan MC, Owen MJ, Williams J**  
Genetic evidence implicates the immune system and cholesterol metabolism in the aetiology of Alzheimer's disease.  
PLoS One 2010; 5: e13950.
59. **Juckel G, Schumacher C, Giegling I, Assion HJ, Mavrogiorgou P, Pogarell O, Mulert C, Hegerl U, Norra C, Rujescu D**  
Serotonergic functioning as measured by the loudness dependence of auditory evoked potentials is related to a haplotype in the brain-derived neurotrophic factor (BDNF) gene.  
J Psychiatr Res 2010; 44: 541-546.
60. **Karch S, Feuerecker R, Leicht G, Meindl T, Hantschk I, Kirsch V, Ertl M, Lutz J, Pogarell O, Mulert C**  
Separating distinct aspects of the voluntary selection between response alternatives: N2- and P3-related BOLD responses.  
Neuroimage 2010; 51: 356-364.
61. **Karch S, Mulert C**  
Cognition.  
In: Mulert C, Lemieux L (Eds).  
EEG-fMRI: Physiology, Technique and Applications.  
Springer, Berlin, 2010, pp 419-449.
62. **Karch S, Thalmeier T, Lutz J, Cerovecki A, Opgen-Rhein M, Hock B, Leicht G, Hennig-Fast C, Meindl T, Riedel M, Mulert N, Pogarell O**  
Neural correlates (ERP/fMRI) of voluntary selection in adult ADHD patients.  
Eur Arch Psychiatry Clin Neurosci 2010; 260: 427-440.

63. **Kasper S, Gastpar M, Möller H-J, Müller WE, Volz HP, Dienel A, Kieser M**  
Better tolerability of St. John's wort extract WS 5570 compared to treatment with SSRIs: a reanalysis of data from controlled clinical trials in acute major depression.  
Int Clin Psychopharmacol 2010; 25: 204-213.
64. **Kasper S, Gastpar M, Müller WE, Volz HP, Möller H-J, Dienel A, Schlafke S**  
Efficacy and safety of silexan, a new, orally administered lavender oil preparation, in subthreshold anxiety disorder - evidence from clinical trials.  
Wien Med Wochenschr 2010; 160: 547-556.
65. **Kasper S, Gastpar M, Müller WE, Volz HP, Möller H-J, Dienel A, Schlafke S**  
Silexan, an orally administered Lavandula oil preparation, is effective in the treatment of 'subsyndromal' anxiety disorder: a randomized, double-blind, placebo controlled trial.  
Int Clin Psychopharmacol 2010; 25: 277-287.
66. **Kasper S, Möller H-J, Hale A**  
The european post-marketing observational Sertindole study: an investigation of the safety of antipsychotic drug treatment.  
Eur Arch Psychiatry Clin Neurosci 2010; 260: 59-68.
67. **Kasper S, Montgomery SA, Möller H-J, van Oers HJ, Jan SA, Vrijland P, van der Meulen EA**  
Longitudinal analysis of the suicidal behaviour risk in short-term placebo-controlled studies of mirtazapine in major depressive disorder.  
World J Biol Psychiatry 2010; 11: 36-44.
68. **Koutsouleris N, Gaser C, Bottlender R, Davatzikos C, Decker P, Jäger M, Schmitt G, Reiser M, Möller H-J, Meisenzahl EM**  
Use of neuroanatomical pattern regression to predict the structural brain dynamics of vulnerability and transition to psychosis.  
Schizophr Res 2010; 123: 175-187.

69. **Koutsouleris N, Patschurek-Kliche K, Scheuerecker J, Decker P, Bottlender R, Schmitt G, Rujescu D, Giegling I, Gaser C, Reiser M, Möller H-J, Meisenzahl EM**  
Neuroanatomical correlates of executive dysfunction in the at-risk mental state for psychosis.  
Schizophr Res 2010; 123: 160-174.
70. **Krause D, Matz J, Weidinger E, Wagner J, Wildenauer A, Obermeier M, Riedel M, Müller N**  
The association of infectious agents and schizophrenia.  
World J Biol Psychiatry 2010; 11: 739-743.
71. **Kumari V, Ettinger U**  
Latent inhibition in schizophrenia and schizotypy: a review of the empirical literature. Chapter 17 in Lubow R, Weiner I (Ed.).  
Latent Inhibition: Cognition, Neuroscience, and Applications to Schizophrenia, Cambridge University Press, 2010, pp. 419-447.
72. **Laux G, Brunnauer A**  
Fahrtauglichkeit unter Antipsychotika  
In: Möller H-J, Müller N (Hrsg.)  
Schizophrenie – Zukunftsperspektiven in Klinik und Forschung.  
Springer, Wien, 2010.
73. **Leicht G, Kirsch V, Giegling I, Karch S, Hantschk I, Möller H-J, Pogarell O, Hegerl U, Rujescu D, Mulert C**  
Reduced early auditory evoked gamma-band response in patients with schizophrenia.  
Biol Psychiatry 2010; 67: 224-231.
74. **Lieb M, Wittchen H-U, Palm U, Apelt SM, Siegert J, Soyka M**  
Psychiatric comorbidity in substitution treatment of opioid-dependent patients in primary care: Prevalence and impact on clinical features.  
Heroin Addict Relat Clin Probl 2010; 12: 5-16.

75. **Liu JZ, Tozzi F, Waterworth DM, Pillai SG, Muglia P, Middleton L, Berrettini W, Knouff CW, Yuan X, Waeber G, Vollenweider P, Preisig M, Wareham NJ, Zhao JH, Loos RJ, Barroso I, Khaw KT, Grundy S, Barter P, Mahley R, Kesaniemi A, McPherson R, Vincent JB, Strauss J, Kennedy JL, Farmer A, McGuffin P, Day R, Matthews K, Bakke P, Gulsvik A, Lucae S, Ising M, Brueckl T, Horstmann S, Wichmann HE, Rawal R, Dahmen N, Lamina C, Polasek O, Zgaga L, Huffman J, Campbell S, Kooner J, Chambers JC, Burnett MS, Devaney JM, Pichard AD, Kent KM, Satler L, Lindsay JM, Waksman R, Epstein S, Wilson JF, Wild SH, Campbell H, Vitart V, Reilly MP, Li M, Qu L, Wilensky R, Matthai W, Hakonarson HH, Rader DJ, Franke A, Wittig M, Schäfer A, Uda M, Terracciano A, Xiao X, Busonero F, Scheet P, Schlessinger D, St Clair D, Rujescu D, Abecasis GR, Grabe HJ, Teumer A, Völzke H, Petersmann A, John U, Rudan I, Hayward C, Wright AF, Kolcic I, Wright BJ, Thompson JR, Balmforth AJ, Hall AS, Samani NJ, Anderson CA, Ahmad T, Mathew CG, Parkes M, Satsangi J, Caulfield M, Munroe PB, Farrall M, Dominiczak A, Worthington J, Thomson W, Eyre S, Barton A, Mooser V, Francks C, Marchini J**  
Meta-analysis and imputation refines the association of 15q25 with smoking quantity.  
Nat Genet 2010; 42: 436-440.
76. **Maier W, Möller H-J**  
Meta-analyses: a method to maximise the evidence from clinical studies?  
Eur Arch Psychiatry Clin Neurosci 2010; 260: 17-23.
77. **Maier W, Rujescu D**  
Gemeinsame Risikogene von affektiven und schizophrenen Erkrankungen.  
In: Möller H-J, Müller N (Hrsg.)  
Schizophrenie – Zukunftsperspektiven in Klinik und Forschung.  
Springer, Wien, 2010, S. 93-103.
78. **Mavorgiorgou P, Gohle D, Winter C, Rujescu D, Pogarell O, Mulert C, Bar KJ, Zaudig M, Hegerl U, Juckel G**  
Low serotonergic function and its normalization by treatment with sertraline in obsessive-compulsive disorder - an auditory evoked potential study.  
J Clin Psychopharmacol 2010; 30: 341-342.

79. **Meisenzahl EM, Möller H-J**  
Strukturelle Verlaufsuntersuchungen bei funktionellen Psychosen.  
In: Möller H-J, Müller N (Hrsg.)  
Schizophrenie - Zukunftsperspektiven in Klinik und Forschung.  
Springer, Wien, 2010, S. 53-57.
80. **Meisenzahl EM, Seifert D, Bottlender R, Teipel S, Zetzsche T, Jäger M, Koutsouleris N, Schmitt G, Scheuerecker J, Burgermeister B, Hampel H, Rupprecht T, Born C, Reiser M, Möller H-J, Frodl T**  
Differences in hippocampal volume between major depression and schizophrenia: a comparative neuroimaging study.  
Eur Arch Psychiatry Clin Neurosci 2010; 260: 127-137.
81. **Mobascher A, Rujescu D, Mittelstrass K, Giegling I, Lamina C, Nitz B, Brenner H, Fehr C, Breitling LP, Gallinat J, Rothenbacher D, Raum E, Müller H, Ruppert A, Hartmann AM, Möller H-J, Gal A, Gieger C, Wichmann HE, Illig T, Dahmen N, Winterer G**  
Association of a variant in the muscarinic acetylcholine receptor 2 gene (CHRM2) with nicotine addiction.  
Am J Med Genet B Neuropsychiatr Genet 2010; 153B: 684-690.
82. **Möller H-J**  
Bipolare affektive Erkrankung.  
Nervenarzt 2010; 81: 523-524.
83. **Möller H-J**  
Der besondere Stellenwert von Antipsychotika der zweiten Generation in der Therapie schizophrener und affektiver Psychosen.  
In: Möller H-J, Müller N (Hrsg.)  
Schizophrenie – Zukunftsperspektiven in Klinik und Forschung.  
Springer, Wien, 2010, S. 187-195.
84. **Möller H-J**  
Le nuove frontiere della psicofarmacologia: focus su antipsicotici e antidepressivi.  
In: Fuirillo A (ed). Lezioni di Psichiatria per il nuovo Millennio.  
Il Pensiero Scientifico Editore, Roma, 2010, p. 43-58.

85. **Möller H-J**  
Long-term pharmacotherapy of schizophrenic patients: Achievements, unsolved needs and future perspectives with special focus on long-acting injectable second generation antipsychotics.  
Arch Psychiatr Psychother 2010; 4: 13-21.
86. **Möller H-J, Broich K**  
Principle standards and problems regarding proof of efficacy in clinical psychopharmacology.  
Eur Arch Psychiatry Clin Neurosci 2010; 260: 3-16.
87. **Möller H-J, Broich K**  
Wirksamkeitsnachweis/Placeboproblematik.  
In: Riederer PF, Laux G (Hrsg). Grundlagen der Neuro-Psychopharmakologie. Ein Therapiehandbuch.  
Springer, Wien, 2010, S. 255-277.
88. **Möller H-J, Jäger M, Riedel M, Obermeier M, Strauss A, Bottlender R**  
The Munich 15-year follow-up study (MUFSSAD) on first-hospitalized patients with schizophrenic or affective disorders: Assessing courses, types and time stability of diagnostic classification.  
Eur Arch Psychiatry Clin Neurosci 2010; 260: 367-384.
89. **Möller H-J, Maier W**  
Evidence-based medicine in psychopharmacotherapy: possibilities, problems and limitations.  
Eur Arch Psychiatry Clin Neurosci 2010; 260: 25-39.
90. **Möller H-J, Müller N** (Hrsg.)  
Schizophrenie – Zukunftsperspektiven in Klinik und Forschung.  
Springer, Wien, 2010.
91. **Möller HJ, Rujescu D**  
Pharmacogenetics - genomics and personalized psychiatry.  
Eur Psychiatry 2010; 25: 291-293.
92. **Möller H-J, Schennach-Wolff R, Seemüller F**  
Core symptoms in major depression.  
Depression in clinical Practice. WPA Bulletin on depression.  
2010; 16: 3-7.

93. **Möller H-J, Schnitker J, Flürenbrock W**  
Factors associated with response in depressed elderly outpatients treated with Escitalopram in a naturalistic setting in Germany.  
Pharmacopsychiatry 2010; 43: 210-215.
94. **Möller H-J, Seemüller F, Riedel M**  
Time and depression treatment: the value of early treatment response.  
Medicographia 2010; 32: 139-145.
95. **Möller-Leimkühler AM**  
Depressionen bei Männern – eine Einführung.  
J Neurol Neurochir Psychiatr 2010; 11: 11-20.
96. **Möller-Leimkühler AM**  
Higher comorbidity of depression and cardiovascular disease in women: a biopsychosocial perspective.  
World J Biol Psychiatry 2010; 11: 922-933.
97. **Möller-Leimkühler AM**  
Psychosoziale Determinanten männlicher Aggression und Gewalt.  
J Neurol Neurochir Psychiatr 2010; 11: 70-77.
98. **Möller-Leimkühler AM, Kasper S**  
Psychische und Verhaltensstörungen.  
Bardehle D, Stiehler M (Hrsg).  
Erster deutscher Männergesundheitsbericht.  
Zuckerschwerdt, München, 2010, S. 135-159.
99. **Möller-Leimkühler AM, Yücel M**  
Male depression in females?  
J Affective Disord 2010; 121: 22-29.
100. **Müller N, Krause D, Dehning S, Musil R, Schennach-Wolff R, Obermeier M, Möller H-J, Klauss V, Schwarz MJ, Riedel M**  
Celecoxib treatment in an early stage of schizophrenia: results of a randomized, double-blind, placebo-controlled trial of celecoxib augmentation of amisulpride treatment.  
Schizophr Res 2010; 121: 118-124.



101. **Müller N, Schwarz MJ**  
Entzündliche Veränderungen als gemeinsamer Pathogenese affektiver und schizophrener Erkrankungen.  
In: Möller H-J, Müller N (Hrsg.)  
Schizophrenie – Zukunftsperspektiven in Klinik und Forschung.  
Springer, Wien, 2010, S. 59-91.
102. **Müller N, Schwarz MJ**  
Immune System and Schizophrenia.  
Curr Immunol Rev 2010; 6: 213-220.
103. **Mulert C, Leicht G, Hepp P, Kirsch V, Karch S, Pogarell O, Reiser M, Hegerl U, Jäger L, Möller H-J, McCarley RW**  
Single-trial coupling of the gamma-band response and the corresponding BOLD signal.  
Neuroimage 2010; 49: 2238-2247.
104. **Mundt A, Ströhle A, Heimann H, Heinz A, Grohmann R**  
Pharmacoepidemiology of patients hospitalized for somatoform disorders in psychiatric hospitals and departments.  
Pharmacoepidemiology and Drug Safety 2010; 19: 687-693.
105. **Nazirizadeh Y, Vogel F, Bader W, Haen E, Pfuhlmann B, Gründer G, Paulzen M, Schwarz M, Zernig G, Hiemke C**  
Serum concentrations of paliperidone versus risperidone and clinical effects.  
Eur J Clin Pharmacol 2010; 66: 797-803.
106. **Nedopil N**  
Der Einfluss der Forschung auf die Praxis der forensischen Psychiatrie.  
In: Saimeh N (Hrsg). Kriminalität als biologisches Scheitern – Forensik als Lebenshilfe?  
Materialien der 25. Eickelborner Fachtagung zu Fragen der Forensischen Psychiatrie, 3. bis 5. März 2010.  
Psychiatrie Verlag, Lippstadt, 2010, S. 35-49.
107. **Nedopil N**  
Der freie Wille und die Schuldfähigkeit aus der Perspektive des forensisch-psychiatrischen Gutachters.  
In: Stompe T, Schanda H (Hrsg). Der freie Wille und die Schuldfähigkeit.  
Medizinisch wissenschaftliche Verlagsgesellschaft, Berlin, S. 209-222.

108. **Nedopil N**  
Forensische Psychiatrie im deutschen Strafrecht – Schuldfähigkeit und Risikoeinschätzung am Beispiel psychotischer Patienten.  
In: Häßler F, Kinze W, Nedopil N (Hrsg). Praxishandbuch Forensische Psychiatrie des Kindes-, Jugend- und Erwachsenenalters.  
Medizinisch Wissenschaftliche Verlagsgesellschaft, Berlin, 2010, S. 681-696.
109. **Nedopil N**  
Forschungsstand, Forschungsbedarf und Forschungsmöglichkeiten in der forensischen Psychiatrie.  
In: Müller JL (Hrsg). Neurobiologie forensisch relevanter Störungen.  
Kohlhammer, Stuttgart, 2010, S. 59-70.
110. **Nedopil N**  
Freiraum für den menschlichen Willen. Gedanken zu einem überflüssigen und unlösbaren Disput.  
In: Dölling D, Götting B, Meier B-D, Verrel T (Hrsg).  
Verbrechen – Strafe – Resozialisierung. Festschrift für Heinz Schöch zum 70. Geburtstag am 20. August 2010.  
de Gryter, Berlin, 2010, S. 979-991.
111. **Nedopil N**  
Intensiv- und Serientäter.  
In: Häßler F, Kinze W, Nedopil N (Hrsg). Praxishandbuch Forensische Psychiatrie des Kindes-, Jugend- und Erwachsenenalters.  
Medizinisch Wissenschaftliche Verlagsgesellschaft, Berlin, 2010, S. 395-402.
112. **Nedopil N**  
Manipulation bei der Begutachtung – Simulation, Aggravation und ihre Auswirkungen.  
In: Hartwich P (Hrsg). Der Psychiater als Gutachter. Verlag Wissenschaft und Praxis Dr. Brauner, 2010, S. 47-58.
113. **Nedopil N**  
Rechtliche Grundlagen der Behandlungen. Einwilligung und Ersatzeinwilligung.  
In: Riederer P, Laux G (Hrsg). Grundlagen der Neuro-Psychopharmakologie. Springer, Wien, 2010, S. 589-600.

114. **Nedopil N**  
Risiko und Sicherheit – Prognoseforschung zur bedingten Entlassung aus Straf- und Maßregelvollzug.  
Zeitschrift für Jugendkriminalrecht und Jugendhilfe, 2010; 2: 283-29.
115. **Nedopil N**  
War erwartet der Erwachsenenforensiker von der Kinder- und Jugendpsychiatrie.  
In: Häßler F, Kinze W, Nedopil N (Hrsg). Praxishandbuch Forensische Psychiatrie des Kindes-, Jugend- und Erwachsenenalters.  
Medizinisch Wissenschaftliche Verlagsgesellschaft,  
Berlin, 2010, S. 63-74.
116. **Nicodemus KK, Law AJ, Radulescu E, Luna A, Kolachana B, Vakkalanka R, Rujescu D, Giegling I, Straub RE, McGee K, Gold B, Dean M, Muglia P, Callicott JH, Tan HY, Weinberger DR**  
Biological validation of increased schizophrenia risk with NRG1, ERBB4, and AKT1 epistasis via functional neuroimaging in healthy controls.  
Arch Gen Psychiatry 2010; 67: 991-1001.
117. **Nothdurfter C, Tanasic S, dlk i Benedetto B, Rammes G, Wagner EM, Kirmeier T, Ganai V, Kessler JS, Rein T, Holsboer F, Rupprecht R**  
Impact of lipid raft integrity on 5-HT<sub>3</sub> receptor function and its modulation by antidepressants.  
Neuropsychopharmacology 2010; 35: 1510-1519.
118. **Oades RD, Dauvermann MR, Schimmelmann BG, Schwarz MJ, Myint A-M**  
Attention-deficit hyperactivity disorder (ADHD) and glial integrity: S100B, cytokines and kynurenine metabolism – effects of medication.  
Behav Brain Funct 2010; 6: 29.
119. **Oades RD, Myint A-M, Dauvermann MR, Schimmelmann BG, Schwarz MJ**  
Attention-deficit hyperactivity disorder (ADHD) and glial integrity: an exploration of associations of cytokines and kynurenine metabolites with symptoms and attention.  
Behav Brain Funct 2010; 6: 32.

120. **Obermeier M, Mayr A, Schennach-Wolff R, Seemüller F, Möller H-J, Riedel M**  
Should the PANSS be rescaled?  
Schiz Bull 2010; 36: 455-460.
121. **Petrovsky N, Quednow BB, Ettinger U, Schmechtig A, Mössner R, Collier DA, Kühn K-U, Maier W, Wagner M, Kumari V**  
Sensorimotor gating is associated with CHRNA3 polymorphisms in schizophrenia and healthy volunteers.  
Neuropsychopharmacology 2010; 35: 1429-1439.
122. **Pinheiro AP, Bulik CM, Thornton LM, Sullivan PF, Root TL, Bloss CS, Berrettini WH, Schork NJ, Kaye WH, Bergen AW, Magistretti P, Brandt H, Crawford S, Crow S, Fichter MM, Goldman D, Halmi KA, Johnson C, Kaplan AS, Keel PK, Klump KL, La Via M, Mitchell JE, Strober M, Rotondo A, Treasure J, Woodside DB**  
Association study of 182 candidate genes in anorexia nervosa.  
Am J Med Genet B Neuropsychiatr Genet 2010; 153B: 1070-1080.
123. **Pinheiro AP, Raney TJ, Thornton LM, Fichter MM, Berrettini WH, Goldman D, Halmi KA, Kaplan AS, Strober M, Treasure J, Woodside DB, Kaye WH, Bulik CM**  
Sexual functioning in women with eating disorders.  
Int J Eat Disord 2010; 43: 123-129.
124. **Pogarell O, Möller H-J**  
Abhängigkeitserkrankungen. Neues zur Pharmakotherapie.  
JATROS Neurologie & Psychiatrie 2010; 18: 34-36.
125. **Pompili M, Serafini G, Innamorati M, Möller-Leimkühler AM, Giupponi G, Girardi P, Tatarelli R, Lester D**  
The hypothalamic-pituitary-adrenal axis and serotonin abnormalities: a selective overview for the implications of suicide prevention.  
Eur Arch Psychiatry Clin Neurosci 2010; 260: 583-600.
126. **Preuss UW, Ridinger M, Rujescu D, Fehr C, Koller G, Wodarz N, Bondy B, Soyka M, Wong WM, Zill P**  
No association of alcohol dependence with HOMER 1 and 2 genetic variants.  
Am J Med Genet B Neuropsychiatr Genet 2010; 153B: 1102-1109.

127. **Preuss UW, Zetzsche T, Pogarell O, Mulert C, Frodl T, Müller D, Schmidt G, Born C, Reiser M, Möller H-J, Hegerl U, Meisenzahl EM**  
Anterior cingulum volumetry, auditory P300 in schizophrenia with negative symptoms.  
Psychiatry Res 2010; 183: 133-139.
128. **Quante A, Zeugmann S, Luborzewski A, Schommer N, Langosch J, Born C, Anghelescu I, Wolf J**  
Aripiprazole as adjunct to a mood stabilizer and citalopram in bipolar depression: a randomized placebo-controlled pilot study.  
Hum Psychopharmacol Clin Exp 2010; 25: 126-132.
129. **Riedel M, Möller H-J, Obermeier M, Schennach-Wolff R, Bauer M, Adli M, Kronmüller K, Nickel T, Brieger P, Laux G, Bender W, Heuser I, Zeiler J, Gaebel W, Seemüller F**  
Response and remission criteria in major depression - a validation of current practice.  
J Psychiatr Res 2010; 44: 1063-1068.
130. **Riedel M, Musil R, Seemüller F, Spellmann I, Möller H-J, Schennach-Wolff R**  
Safety evaluation of zotepine for the treatment of schizophrenia.  
Expert Opin Drug Saf 2010; 9: 659-666.
131. **Riedel M, Schennach-Wolff R, Musil R, Dehning S, Cerovecki A, Opgen-Rhein M, Matz J, Seemüller F, Obermeier M, Engel RR, Müller N, Möller HJ, Spellmann I**  
Neurocognition and its influencing factors in the treatment of schizophrenia-effects of aripiprazole, olanzapine, quetiapine and risperidone.  
Hum Psychopharmacol 2010; 25: 116-125.
132. **Riedel M, Spellmann I**  
Kognitive Störungen bei Schizophrenie und ihre Therapie  
In: Möller H-J, Müller N (Hrsg.)  
Schizophrenie – Zukunftsperspektiven in Klinik und Forschung.  
Springer, Wien, 2010, S. 205-217.

133. **Riedel M, Spellmann I, Schennach-Wolff R, Musil R, Dehning S, Cerovecki A, Opgen-Rhein M, Matz J, Seemüller F, Obermeier M, Severus E, Engel RR, Müller N, Möller H-J**  
Effect of aripiprazole on cognition in the treatment of patients with schizophrenia.  
Pharmacopsychiatry 2010; 43: 50-57.
134. **Root TL, Pinheiro AP, Thornton L, Strober M, Fernandez-Aranda F, Brandt H, Crawford S, Fichter MM, Halmi KA, Johnson C, Kaplan AS, Klump KL, La Via M, Mitchell J, Woodside DB, Rotondo A, Berrettini WH, Kaye WH, Bulik CM**  
Substance use disorders in women with anorexia nervosa.  
Int J Eat Disord 2010; 43: 14-21.
135. **Rösner S, Hackl-Herrwerth A, Leucht S, Lehert P, Vecchi S, Soyka M**  
Acamprosate for alcohol dependence.  
Cochrane Database Syst Rev 2010; CD004332.
136. **Rösner S, Hackl-Herrwerth A, Leucht S, Vecchi S, Srisurapanont M, Soyka M**  
Opioid antagonists for alcohol dependence.  
Cochrane Database Syst Rev 2010; 12: CD001867.
137. **Rujescu D**  
Neue Ergebnisse in der genetischen Forschung bei schizophrenen Psychosen  
In: Möller H-J, Müller N (Hrsg.)  
Schizophrenie – Zukunftsperspektiven in Klinik und Forschung.  
Springer, Wien, 2010, S. 133-141.
138. **Rujescu D, Giegling I**  
The genetics of neurosystems in mental ill-health and suicidality: beyond serotonin.  
Eur Psychiatry 2010; 25: 272-274.
139. **Rupprecht R, Papadopoulos V, Rammes G, Baghai TC, Fan J, Akula N, Groyer G, Adams D, Schumacher M**  
Translocator protein (18 kDa) (TSPO) as a therapeutic target for neurological and psychiatric disorders.  
Nat Rev Drug Discov 2010; 9: 971-988.

140. **Saccone NL, Culverhouse RC, Schwantes-An TH, Cannon DS, Chen X, Cichon S, Giegling I, Han S, Han Y, Keskitalo-Vuokko K, Kong X, Landi MT, Ma JZ, Short SE, Stephens SH, Stevens VL, Sun L, Wang Y, Wenzlaff AS, Aggen SH, Breslau N, Broderick P, Chatterjee N, Chen J, Heath AC, Heliövaara M, Hoft NR, Hunter DJ, Jensen MK, Martin NG, Montgomery GW, Niu T, Payne TJ, Peltonen L, Pergadia ML, Rice JP, Sherva R, Spitz MR, Sun J, Wang JC, Weiss RB, Wheeler W, Witt SH, Yang BZ, Caporaso NE, Ehringer MA, Eisen T, Gapstur SM, Gelernter J, Houlston R, Kaprio J, Kendler KS, Kraft P, Leppert MF, Li MD, Madden PA, Nothen MM, Pillai S, Rietschel M, Rujescu D, Schwartz A, Amos CI, Bierut LJ**  
Multiple independent loci at chromosome 15q25.1 affect smoking quantity: a meta-analysis and comparison with lung cancer and COPD. *PLoS Genet* 2010; 6: e1001053.
141. **Santangelo de Souza D, Riedel M, Möller H-J, Severus E**  
Bipolare Störungen. Therapiemöglichkeiten zwischen Hoch und Tief. *MMW Fortschr Med* 2010; 152: 50-52.
142. **Schaub A**  
Evidenzbasierte Gruppentherapie bei schizophrenen Psychosen. *Zeitschrift für Psychiatrie, Psychologie und Psychotherapie* 2010; 58: 103-109.
143. **Schaub A**  
Kognitiv-psychoedukative Gruppenintervention bei stationären Patienten mit schizophrenen oder affektiven Erkrankungen.  
In: Möller H-J, Müller N (Hrsg.)  
Springer, Wien, 2010, S. 267-279.
144. **Schaub A, Frank R**  
Sprechstunde für Kinder psychische kranker Eltern.  
*Monatsschr Kinderheilk* 2010; 158: 858-867.
145. **Schennach-Wolff R, Jäger M, Obermeier M, Schmauss M, Laux G, Pfeiffer H, Naber D, Schmidt LG, Gaebel W, Klosterkötter J, Heuser I, Kühn KU, Lemke MR, Rüther E, Klingberg S, Gastpar M, Seemüller F, Möller H-J, Riedel M**  
Quality of life and subjective well-being in schizophrenia and schizophrenia spectrum disorders: valid predictors of symptomatic response and remission?  
*World J Biol Psychiatry* 2010; 11: 729-738.

146. **Schennach-Wolff R, Jäger M, Seemüller F, Obermeier M, Schmauss M, Laux G, Pfeiffer H, Naber D, Schmidt LG, Gaebel W, Klosterkötter J, Heuser I, Maier W, Lemke MR, Rütther E, Klingberg S, Gastpar M, Möller H-J, Riedel M**  
Outcome of suicidal patients with schizophrenia: results from a naturalistic study.  
Acta Psychiatr Scand 2010; 121: 359-370.
147. **Schennach-Wolff R, Möller H-J, Jäger M, Seemüller F, Obermeier M, Messer T, Laux G, Pfeiffer H, Naber D, Schmidt LG, Gaebel W, Klosterkötter J, Heuser I, Maier W, Lemke MR, Rütther E, Klingberg S, Gastpar M, Riedel M**  
A critical analysis and discussion of the appropriateness of the schizophrenia consensus remission criteria in clinical pharmaceutical trials.  
Pharmacopsychiatry 2010; 43: 245-251.
148. **Schennach-Wolff R, Obermeier M, Seemüller F, Jäger M, Schmauss M, Laux G, Pfeiffer H, Naber D, Schmidt LG, Gaebel W, Klosterkötter J, Heuser I, Maier W, Lemke MR, Rütther E, Klingberg S, Gastpar M, Engel RR, Möller H-J, Riedel M**  
Does clinical judgment of baseline severity and changes in psychopathology depend on the patient population? Results of a CGI and PANSS linking analysis in a naturalistic study.  
J Clin Psychopharmacol 2010; 30: 726-731.
149. **Schennach-Wolff R, Seemüller FH, Mayr A, Maier W, Klingberg S, Heuser I, Klosterkötter J, Gastpar M, Häfner H, Sauer H, Schneider F, Gaebel W, Jäger M, Möller H-J, Riedel M**  
An early improvement threshold to predict response and remission in first-episode schizophrenia.  
Br J Psychiatry 2010; 196: 460-466.
150. **Schennach-Wolff R, Stübner S, Riedel M, Müller N**  
Extensive elevation of creatine kinase with generic clozapine, but not with Leponex.  
Psychiatry Res 2010; 176: 93.
151. **Scheuerecker J, Meisenzahl EM, Koutsouleris N, Roesner M, Schöpf V, Linn J, Wiesmann M, Brückmann H, Möller H-J, Frodl T**  
Orbitofrontal volume reductions during emotion recognition in patients with major depression.  
J Psychiatry Neurosci 2010; 35: 311-320.



152. **Schmahl C, Meinzer M, Zeuch A, Fichter M, Cebulla M, Kleindienst N, Ludascher P, Steil R, Bohus M**  
Pain sensitivity is reduced in borderline personality disorder, but not in posttraumatic stress disorder and bulimia nervosa.  
World J Biol Psychiatry 2010; 11: 364-371.
153. **Schüle C, Baghai TC, di Michele F, Eser D, Pasini A, Romeo E, Rupprecht R**  
Mirtazapine does not influence tetrahydrodeoxycorticosterone levels in depressed patients.  
World J Biol Psychiatry 2010; 11: 308-313.
154. **Schwarz MJ, Musil R, Spellmann I, Opgen-Rhein M, Jurgeleit F, Sirch W, Sterz S, Zach J, Riedel M**  
Therapeutisches Drug-Monitoring neuerer atypischer Antipsychotika  
In: Möller H-J, Müller N (Hrsg.)  
Schizophrenie – Zukunftsperspektiven in Klinik und Forschung.  
Springer, Wien, 2010, S. 229-241.
155. **Seemüller F, Möller H-J, Obermeier M, Adli M, Bauer M, Kronmüller K, Holsboer F, Brieger P, Laux G, Bender W, Heuser I, Zeiler J, Gaebel W, Schennach-Wolff R, Henkel V, Riedel M**  
Do efficacy and effectiveness samples differ in antidepressant treatment outcome? an analysis of eligibility criteria in randomized controlled trials.  
J Clin Psychiatry 2010; 71: 1425-1433.
156. **Seemüller F, Möller H-J, Obermeier M, Schennach-Wolff R, Riedel M**  
Commentary zu: Stone M. Review: Antidepressants associated with increased risk of suicidality in adults aged less than 25 years.  
EBMH 2010; 13: 52.
157. **Seemüller F, Riedel M, Dargel S, Djaja N, Schennach-Wolff R, Dittmann S, Möller H-J, Severus E**  
Bipolare Depression. Spektrum klinischer Erscheinungsbilder und Abgrenzbarkeit von der unipolaren Depression.  
Nervenarzt 2010; 81: 531-538.

158. **Seemüller F, Riedel M, Obermeier M, Bauer M, Adli M, Kronmüller K, Holsboer F, Brieger P, Laux G, Bender W, Heuser I, Zeiler J, Gaebel W, Dichgans E, Bottlander R, Musil R, Möller H-J**  
Outcomes of 1014 naturalistically treated inpatients with major depressive episode.  
Eur Neuropsychopharmacol 2010; 20: 346-355.
159. **Seemüller F, Schennach-Wolff R, Obermeier M, Henkel V, Möller H-J, Riedel M**  
Does early improvement in major depression protect against treatment emergent suicidal ideation?  
J Affect Disord 2010; 124: 183-186.
160. **Selby EA, Smith AR, Bulik CM, Olmsted MP, Thornton L, McFarlane TL, Berrettini WH, Brandt HA, Crawford S, Fichter MM, Halmi KA, Jacoby GE, Johnson CL, Jones I, Kaplan AS, Mitchell JE, Nutzinger DO, Strober M, Treasure J, Woodside DB, Kaye WH, Joiner TE, Jr.**  
Habitual starvation and provocative behaviors: two potential routes to extreme suicidal behavior in anorexia nervosa.  
Behav Res Ther 2010; 48: 634-645.
161. **Severus WE, Lipkovich IA, Licht RW, Young AH, Greil W, Ketter T, Deberdt W, Tohen M**  
In search of optimal lithium levels and olanzapine doses in the long-term treatment of bipolar I disorder. A post-hoc analysis of the maintenance study by Tohen et al. 2005  
Eur Psychiatry 2010; 25: 443-449.
162. **Shuman NK, Krug I, Maxwell M, Pinheiro AP, Brewerton T, Thornton LM, Berrettini WH, Brandt H, Crawford S, Crow S, Fichter MM, Halmi KA, Johnson C, Kaplan AS, Keel P, Lavia M, Mitchell J, Rotondo A, Strober M, Woodside DB, Kaye WH, Bulik CM**  
Is season of birth related to disordered eating and personality in women with eating disorders?  
Eat Weight Disord 2010; 15: e186-e189.
163. **Soyka M**  
Alkoholinduzierte psychotische Störungen - eine Übersicht.  
Suchtmed 2010; 12: 21-28.

164. **Soyka M**  
Drogennotfälle.  
Diagnostik, Klinisches Erscheinungsbild, Therapie.  
Schattauer, 2010.
165. **Soyka M**  
Klinisch-psychiatrische Diagnostik des Alkoholismus.  
In: Singer MS, Batra A, Mann K (Hrsg.)  
Alkohol und Tabak. Thieme, Göttingen, 2010, S. 501-512.
166. **Soyka M**  
Neuro-Doping  
In: Spitzer G, Franke E (Hrsg.)  
Sport, Doping und Enhancement – Transdisziplinäre Perspektiven.  
Sportverlag Strauß, Köln, 2010, S. 225-233.
167. **Soyka M**  
Neuro-Enhancement - eine kritische Annäherung.  
Arbeitsmed Sozialmed Umweltmed 2010; 45: 242-246.
168. **Soyka M**  
Sucht und Suizid bei Ärzten. Wenn die Helfer schlapp machen.  
MMW Fortschr Med 2010; 152: 27-29.
169. **Soyka M**  
To substitute or not substitute - optimal tactics for the management of  
Benzodiazepine dependence.  
Addiction 2010; 105: 1876-1877.
170. **Soyka M**  
Viele Kollegen sind chronisch überlastet. Wie steht es um Ihre  
psychische Gesundheit?  
MMW Fortschr Med 2010; 152: 26.
171. **Soyka M, Helten C, Schmidt P**  
OCDS craving scores predict 24-month outcome in alcoholic outpatients.  
Am J Addict 2010; 19: 264-269.
172. **Soyka M, Rösner S**  
Emerging drugs to treat alcoholism.  
Expert Opin Emerg Drugs 2010; 15: 695-711.

173. **Soyka M, Rösner S**  
Nalmefene for treatment of alcohol dependence.  
Expert Opin Investig Drugs 2010; 19: 1451-1459.
174. **Soyka M, Zingg C**  
Association for methodology and documentation in psychiatry profiles predict later risk for criminal behavior and violent crimes in former inpatients with affective disorder.  
J Forensic Sci 2010; 55: 655-659.
175. **Soyka M, Zingg C, Koller G, Hennig-Fast K**  
Cognitive function in short- and long-term substitution treatment: Are there differences?  
World J Biol Psychiatry 2010; 11: 400-408.
176. **Sperling W, Reulbach U, Bleich S, Padberg F, Kornhuber J, Mueck-Weymann M**  
Cardiac effects of vagus nerve stimulation in patients with major depression.  
Pharmacopsychiatry 2010; 43: 7-11.
177. **Stadtland C, Nedopil N**  
Ein neues Konzept zur Risikoeinschätzung bei Sexualstraftätern.  
In: Hahn G, Stiels-Glenn M (Hrsg):  
Ambulante Täterarbeit. Intervention, Risikokontrolle und Prävention.  
Psychiatrie Verlag, Bonn, 2010, S. 62-78.
178. **Steiner J, Myint AM, Schiltz K, Westphal S, Bernstein H-G, Walter M, Schroeter ML, Schwarz MJ, Bogerts B**  
S100B Serum levels in schizophrenia are presumably related to visceral obesity and insulin resistance.  
Cardiovasc Psychiatry Neurol 2010; 480707.
179. **Steiner J, Walter M, Guest P, Myint AM, Schiltz K, Panteli B, Brauner M, Bernstein H-G, Gos T, Herberth M, Schroeter ML, Schwarz MJ, Westphal S, Bahn S, Bogerts B**  
Elevated S100B levels in schizophrenia are associated with insulin resistance.  
Mol Psychiatry 2010; 15: 3-4.

180. **Stübner S, Grohmann R, von S, I, Rüter E, Möller H-J, Müller-Oerlinghausen B, Engel RR, Horvath A, Greil W**  
Suicidality as rare adverse event of antidepressant medication: report from the AMSP multicenter drug safety surveillance project.  
J Clin Psychiatry 2010; 71: 1293-1307.
181. **Stübner S, Nedopil N**  
Ambulante Sicherungsnachsorge in Bayern: Bericht über das erste Modellprojekt.  
In: Hahn G, Stiels-Glenn M (Hrsg):  
Ambulante Täterarbeit. Intervention, Risikokontrolle und Prävention.  
Psychiatrie Verlag, Bonn, 2010, S. 172-188.
182. **Teipel SJ, Bokde AL, Meindl T, Amaro E Jr, Soldner J, Reiser MF, Herpertz SC, Möller H-J, Hampel H**  
White matter microstructure underlying default mode network connectivity in the human brain.  
Neuroimage 2010; 49: 2021-2032.
183. **Thorgeirsson TE, Gudbjartsson DF, Surakka I, Vink JM, Amin N, Geller F, Sulem P, Rafnar T, Esko T, Walter S, Gieger C, Rawal R, Mangino M, Prokopenko I, Mägi R, Keskitalo K, Gudjonsdottir IH, Gretarsdottir S, Stefansson H, Thompson JR, Aulchenko YS, Nelis M, Aben KK, den Heijer M, Dirksen A, Ashraf H, Soranzo N, Valdes AM, Steves C, Uitterlinden AG, Hofman A, Tonjes A, Kovacs P, Hottenga JJ, Willemsen G, Vogelzangs N, Doring A, Dahmen N, Nitz B, Pergadia ML, Saez B, De D, V, Lezcano V, Garcia-Prats MD, Ripatti S, Perola M, Kettunen J, Hartikainen AL, Pouta A, Laitinen J, Isohanni M, Huei-Yi S, Allen M, Krestyaninova M, Hall AS, Jones GT, van Rij AM, Mueller T, Dieplinger B, Haltmayer M, Jonsson S, Matthiasson SE, Oskarsson H, Tyrfingsson T, Kiemeny LA, Mayordomo JI, Lindholt JS, Pedersen JH, Franklin WA, Wolf H, Montgomery GW, Heath AC, Martin NG, Madden PA, Giegling I, Rujescu D, Järvelin MR, Salomaa V, Stumvoll M, Spector TD, Wichmann HE, Metspalu A, Samani NJ, Penninx BW, Oostra BA, Boomsma DI, Tiemeier H, van Duijn CM, Kaprio J, Gulcher JR, McCarthy MI, Peltonen L, Thorsteinsdottir U, Stefansson K**  
Sequence variants at CHRN3-CHRNA6 and CYP2A6 affect smoking behavior.  
Nat Genet 2010; 42: 448-453.

184. **Tretter F, Rujescu D, Pogarell O, Mendoza E**  
Computational Neuropsychiatry Vol. 5: Systems Biology of the Synapse and Mental disorder. Editorial.  
Pharmacopsychiatry 2010; 43 Suppl 1: S1.
185. **Vassos E, Collier DA, Holden S, Patch C, Rujescu D, St Clair D, Lewis CM**  
Penetrance for copy number variants associated with schizophrenia.  
Hum Mol Genet 2010; 19: 3477-3481.
186. **Volz HP, Reischies F, Riedel M**  
Kognitive Störungen bei schizophrenen Patienten.  
Nervenarzt 2010; 81: 39-54.
187. **Walters JT, Corvin A, Owen MJ, Williams H, Dragovic M, Quinn EM, Judge R, Smith DJ, Norton N, Giegling I, Hartmann AM, Möller H-J, Muglia P, Moskvina V, Dwyer S, O'Donoghue T, Morar B, Cooper M, Chandler D, Jablensky A, Gill M, Kaladjieva L, Morris DW, O'Donovan MC, Rujescu D, Donohoe G**  
Psychosis susceptibility gene ZNF804A and cognitive performance in schizophrenia.  
Arch Gen Psychiatry 2010; 67: 692-700.
188. **Wankerl M, Zyriax BC, Bondy B, Hinkelmann K, Windler E, Otte C**  
Serotonin transporter gene-linked polymorphic region (5-HTTLPR) and diurnal cortisol: A sex by genotype interaction.  
Biol Psychol 2010; 85: 344-346.
189. **Wiethoff K, Bauer M, Baghai TC, Möller H-J, Fisher R, Hollinde D, Kiermeir J, Hauth I, Laux G, Cordes J, Brieger P, Kronmüller KT, Zeiler J, Adli M**  
Prevalence and treatment outcome in anxious versus nonanxious depression: results from the German Algorithm Project.  
J Clin Psychiatry 2010; 71: 1047-1054.
190. **Winterer G, Mittelstrass K, Giegling I, Lamina C, Fehr C, Brenner H, Breitling LP, Nitz B, Raum E, Müller H, Gallinat J, Gal A, Heim K, Prokisch H, Meitinger T, Hartmann AM, Möller H-J, Gieger C, Wichmann HE, Illig T, Dahmen N, Rujescu D**  
Risk gene variants for nicotine dependence in the CHRNA5-CHRNA3-CHRNA4 cluster are associated with cognitive performance.  
Am J Med Genet B Neuropsychiatr Genet 2010; 153B: 1448-58.

191. **Yatham LN, Torres IJ, Malhi GS, Frangou S, Glahn DC, Bearden CE, Burdick KE, Martinez-Arán, Dittmann S, Goldberg JF, Ozerdem A, Aydemir O, Chengappa KN**  
The International Society for Bipolar Disorders-Battery for Assessment of Neurocognition (ISBD-BANC).  
Bipolar Disord 2010; 12: 351-63.
192. **Yundina E, Nedopil N**  
Indirekte Diagnostik pädosexueller Neigungen.  
In: Müller L (Hrsg). Neurobiologie forensisch relevanter Störungen.  
Kohlhammer, Stuttgart, 2010, S. 453-460.
193. **Zetsche T, Rujescu D, Hardy J, Hampel H**  
Advances and perspectives from genetic research: development of biological markers in Alzheimer's disease.  
Expert Rev Mol Diagn 2010; 10: 667-690.